• 1
    Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13201328
  • 2
    Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005; 7 (Suppl. 9): S3S14
  • 3
    Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255260
  • 4
    Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005; 23: 75467554
  • 5
    Briganti A, Chun FK, Suardi N et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007; 43: 26692677
  • 6
    Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993; 20: 653663
  • 7
    Roobol MJ, van Vugt HA, Loeb S et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 577583
  • 8
    Roobol MJ, Schröder FH, Hugosson J et al. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012; 30: 149155
  • 9
    Djavan B, Waldert M, Zlotta A et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166: 856860
  • 10
    Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-medicare. J Urol 2011; 186: 18301834
  • 11
    Nam RK, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963968
  • 12
    Vickers AJ, Cronin AM, Aus G et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008; 6: 19
  • 13
    Vickers A, Cronin A, Roobol M et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010; 28: 24932498
  • 14
    Nurmikko P, Väisänen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000; 46: 16101618
  • 15
    Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001; 47: 14151423
  • 16
    Steuber T, Nurmikko P, Haese A et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002; 168: 19171922
  • 17
    Steuber T, Niemela P, Haese A et al. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005; 63: 1318
  • 18
    Haese A, Graefen M, Steuber T et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003; 170 (6 Pt 1): 22692273
  • 19
    Schalken JA. Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl. 1): 59
  • 20
    Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383391
  • 21
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 13971405
  • 22
    Väisänen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem 2006; 78: 78097815
  • 23
    Väisänen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 2004; 50: 16071617
  • 24
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837845
  • 25
    Ko JS, Landis P, Carter HB, Partin AW. Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int 2011; 108: 17391742
  • 26
    Peltola MT, Niemelä P, Alanen K, Nurmi M, Lilja H, Pettersson K. Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146). J Immunol Methods 2011; 369: 7480
  • 27
    Mikolajczyk SD, Catalona WJ, Evans CL et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: 10171025
  • 28
    Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, Catalona WJ. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 13551359
  • 29
    Guazzoni G, Lazzeri M, Nava L et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455466
  • 30
    Ulmert D, Becker C, Nilsson JA et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at −20 degrees C. Clin Chem 2006; 52: 235239
  • 31
    Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C. Pre-analytical in-vitro stability of [−2]proPSA in blood and serum. Clin Biochem 2010; 43: 926928
  • 32
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 6171